These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 10705202)

  • 1. Prostate-specific antigen levels and clinical response to flutamide as the second hormone therapy for hormone-refractory prostate carcinoma.
    Fujikawa K; Matsui Y; Fukuzawa S; Takeuchi H
    Eur Urol; 2000 Feb; 37(2):218-22. PubMed ID: 10705202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H; Hara I; Eto H
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate.
    Brufsky A; Fontaine-Rothe P; Berlane K; Rieker P; Jiroutek M; Kaplan I; Kaufman D; Kantoff P
    Urology; 1997 Jun; 49(6):913-20. PubMed ID: 9187700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
    Herrada J; Dieringer P; Logothetis CJ
    J Urol; 1996 Feb; 155(2):620-3. PubMed ID: 8558675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective study on the relationship between clinical efficacy of secondary hormone therapy with flutamide and neuroendocrine differentiation in patients with relapsed prostate cancer after first line hormone therapy.
    Hirano D; Hasegawa R; Satoh K; Mochida J; Yamanaka Y; Hirakata H; Yamaguchi K; Sugimoto S; Kawata N; Takahashi S
    Scand J Urol; 2014 Oct; 48(5):436-44. PubMed ID: 24730473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
    Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE
    Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N; Arima K; Sugimura Y
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy.
    Zelefsky MJ; Lyass O; Fuks Z; Wolfe T; Burman C; Ling CC; Leibel SA
    J Clin Oncol; 1998 Oct; 16(10):3380-5. PubMed ID: 9779716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: a single-center experience.
    Okegawa T; Nutahara K; Higashihara E
    Int J Urol; 2010 Nov; 17(11):950-5. PubMed ID: 20807265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer.
    Kwak C; Jeong SJ; Park MS; Lee E; Lee SE
    J Urol; 2002 Sep; 168(3):995-1000. PubMed ID: 12187207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.
    Scher HI; Kelly WK
    J Clin Oncol; 1993 Aug; 11(8):1566-72. PubMed ID: 7687666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Alternative antiandrogen therapy with flutamide in patients with castration-resistant prostate cancer : a single center experience].
    Takada T; Ishizuya Y; Okada T; Ueda T; Inoue H; Hara T
    Hinyokika Kiyo; 2011 Jun; 57(6):291-5. PubMed ID: 21795830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer.
    Robinson D; Sandblom G; Johansson R; Garmo H; Aus G; Hedlund PO; Varenhorst E;
    Urology; 2008 Oct; 72(4):903-7. PubMed ID: 18639324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of radiation therapy combined with neoadjuvant hormonal therapy for stage III prostate cancer: comparison of two different definitions of PSA failure.
    Mitsumori M; Sasaki Y; Mizowaki T; Takayama K; Nagata Y; Hiraoka M; Negoro Y; Sasai K; Kinoshita H; Kamoto T; Ogawa O
    Int J Clin Oncol; 2006 Oct; 11(5):396-402. PubMed ID: 17058138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate specific antigen in black and white men after hormonal therapies for prostate cancer.
    Fowler JE; Bigler SA; Renfroe DL; Dabagia MD
    J Urol; 1997 Jul; 158(1):150-4. PubMed ID: 9186343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.